Apogee Therapeutics Inc
APGE
NASDAQ
Biotechnology
$134.55
USD
+0.10 (+0.07%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $10.18B
Volume 1.5M
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-294.37M
TTM
-23.9%
YoY
Operating Cash Flow
$-243.89M
TTM
-10.5%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 17.5 | 17.1 | 19.6 | 22.0 | 24.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 4.4 |
Total Operating Expenses | 73.2 | 71.3 | 78.1 | 82.8 | 96.0 |
Operating Income | -73.2 | -71.3 | -78.1 | -82.8 | -96.0 |
EBITDA | -72.8 | -70.9 | -77.7 | -82.4 | -91.2 |
Other Income / Expense | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Other Income / Expense | 7.1 | 6.3 | 8.7 | 8.7 | 10.2 |
Income Before Income Taxes | -66.0 | -65.0 | -69.3 | -74.0 | -85.8 |
Income Taxes | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
Net Income | -66.1 | -65.0 | -69.4 | -74.1 | -85.9 |
Consolidated Net Income / Loss | -66.1 | -65.0 | -69.4 | -74.1 | -85.9 |
Net Income Attributable to Common Shareholders | -66.1 | -65.0 | -69.4 | -74.1 | -85.9 |
Basic EPS | -$1.13 | -$1.11 | -$1.03 | -$1.06 | -$1.14 |
Diluted EPS | -$1.13 | -$1.11 | -$1.03 | -$1.06 | -$1.14 |
Basic Shares Outstanding | 58.4M | 58.8M | 67.4M | 69.7M | 75.4M |
Diluted Shares Outstanding | 58.4M | 58.8M | 67.4M | 69.7M | 75.4M |